Is telomerase a viable target in cancer?
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The ideal cancer treatment would specifically target cancer cells yet have minimal or no adverse effects on normal somatic cells. Telomerase, the ribonucleoprotein reverse transcriptase that maintains the ends of human chromosome, is an attractive cancer therapeutic target for exactly this reason [1]. Telomerase is expressed in more than 85% of cancer cells, making it a nearly universal cancer marker, while the majority of normal somatic cells are telomerase negative. Telomerase activity confers limitless replicative potential to cancer cells, a hallmark of cancer which must be attained for the continued growth that characterizes almost all advanced neoplasms [2]. In this review we will summarize the role of telomeres and telomerase in cancer cells, and how properties of telomerase are being exploited to create targeted cancer therapies including telomerase inhibitors, telomerase-targeted immunotherapies and telomerase-driven virotherapies. A frank and balanced assessment of the current state of telomerase inhibitors with caveats and potential limitations will be included.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 3×
“However, telomerase activity is nearly universal in human cancer cell lines, and is found in about 85–90% of primary tumors [29].”
Self-citationShelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 1×
“The shelterin component proteins function to maintain telomere length, promote t-loop formation, recruit telomerase to telomeric ends, and to protect the ends of chromosomes from being recognized as DNA damage [6–8].”
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917 · cited 1×
“In normal cells that lack telomerase, telomere attrition leads to critically short telomeres which trigger a localized DNA damage response [12,16– 19] and p53-mediated cell cycle arrest [12,16,18,20,21].”
A survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794
Self-citationOxidative stress shortens telomeres
von Zglinicki, T. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02110-2 · Cited by 2,524 · cited 1×
“In cells that lack telomerase, telomeres shorten with each cell division due to incomplete replication of the lagging strand, oxidative damage, and telomere processing events that are yet to be fully understood [9–11].”
Mammalian Telomeres End in a Large Duplex Loop
Griffith, J. D., Comeau, L., Rosenfield, S., Stansel, R. M., Bianchi, A., Moss, H., & de Lange, T. (1999) · Cell · doi:10.1016/s0092-8674(00)80760-6 · Cited by 2,447
Telomerase Catalytic Subunit Homologs from Fission Yeast and Human
Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., & Cech, T. R. (1997) · Science · doi:10.1126/science.277.5328.955 · Cited by 2,256 · cited 1×
“The human telomerase holoenzyme core components are a catalytic reverse transcriptase called hTERT (human telomerase reverse transcriptase) [35,36], and an associated template RNA called hTR or hTERC (human Telomerase RNA) [36–39].”
The RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227 · cited 1×
“The human telomerase holoenzyme core components are a catalytic reverse transcriptase called hTERT (human telomerase reverse transcriptase) [35,36], and an associated template RNA called hTR or hTERC (human Telomerase RNA) [36–39].”
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096
Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80538-3 · Cited by 1,784
TRF2 Protects Human Telomeres from End-to-End Fusions
van Steensel, B., Smogorzewska, A., & de Lange, T. (1998) · Cell · doi:10.1016/s0092-8674(00)80932-0 · Cited by 1,709 · cited 1×
“In normal cells that lack telomerase, telomere attrition leads to critically short telomeres which trigger a localized DNA damage response [12,16– 19] and p53-mediated cell cycle arrest [12,16,18,20,21].”
DNA Damage Foci at Dysfunctional Telomeres
Takai, H., Smogorzewska, A., & de Lange, T. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00542-6 · Cited by 1,409
Herbig, U., Jobling, W. A., Chen, B. P. C., Chen, D. J., & Sedivy, J. M. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00256-4 · Cited by 1,344 · cited 1×
“strand breaks at telomeres [12–15].”
Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R. (1997) · Nature Medicine · doi:10.1038/nm1197-1271 · Cited by 1,292 · cited 1×
“The approximately 10% of cancer cells that do not upregulate telomerase have been found either to be “mortal” tumor cells or to maintain their telomeres through a telomere recombination pathway called ALT (alternative lengthening of telomeres) [52].”
p53- and ATM-Dependent Apoptosis Induced by Telomeres Lacking TRF2
Karlseder, J., Broccoli, D., Dai, Y., Hardy, S., & de Lange, T. (1999) · Science · doi:10.1126/science.283.5406.1321 · Cited by 1,086
Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S.-L., Gottlieb, G. J., Greider, C. W., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80762-x · Cited by 979
Human Telomerase and Its Regulation
Cong, Y.-S., Wright, W. E., & Shay, J. W. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.3.407-425.2002 · Cited by 898
Self-citationProtection of telomeres through independent control of ATM and ATR by TRF2 and POT1
Denchi, E. L., & de Lange, T. (2007) · Nature · doi:10.1038/nature06065 · Cited by 880 · cited 1×
“strand breaks at telomeres [12–15].”
A role for both RB and p53 in the regulation of human cellular senescence*1
SHAY, J. (1991) · Experimental Cell Research · doi:10.1016/0014-4827(91)90453-2 · Cited by 757
Self-citationTelomere shortening and apoptosis in telomerase-inhibited human tumor cells
Zhang, X., Mar, V., Zhou, W., Harrington, L., & Robinson, M. O. (1999) · Genes & Development · doi:10.1101/gad.13.18.2388 · Cited by 698 · cited 1×
“These cells ultimately reach a crisis stage [23,24] which is marked by genomic instability due to chromosome end fusions and increased aneuploidy, and leads to p53-independent apoptosis [25,26].”
Protein Composition of Catalytically Active Human Telomerase from Immortal Cells
Cohen, S. B., Graham, M. E., Lovrecz, G. O., Bache, N., Robinson, P. J., & Reddel, R. R. (2007) · Science · doi:10.1126/science.1138596 · Cited by 669 · cited 1×
“A recent purification strategy was designed to isolate only catalytically active telomerase, revealing that only one additional component, dyskerin, was required for in vitro telomerase activity [45].”
Correlating telomerase activity levels with human neuroblastoma outcomes
Hiyama, E., Hiyama, K., Yokoyama, T., Matsuura, Y., Piatyszek, M. A., & Shay, J. W. (1995) · Nature Medicine · doi:10.1038/nm0395-249 · Cited by 611
Self-citationHuman telomerase contains evolutionarily conserved catalytic and structural subunits
Harrington, L., Zhou, W., McPhail, T., Oulton, R., Yeung, D. S. K., Mar, V., Bass, M. B., & Robinson, M. O. (1997) · Genes & Development · doi:10.1101/gad.11.23.3109 · Cited by 465
Su, Z., Dannull, J., Yang, B. K., Dahm, P., Coleman, D., Yancey, D., Sichi, S., Niedzwiecki, D., Boczkowski, D., Gilboa, E., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3798 · Cited by 359 · cited 4×
“Multiple vaccine strategies are being developed and tested in patients with melanoma, lung, prostate, breast, and pancreatic cancers [89,91,92,96,99,112,113], and these trials have generally produced a specific immune response against hTERT positive tumor cells.”
InfluentialUnderstanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers
Kyo, S., Takakura, M., Fujiwara, T., & Inoue, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00878.x · Cited by 347
Does a Sentinel or a Subset of Short Telomeres Determine Replicative Senescence?
Zou, Y., Sfeir, A., Gryaznov, S. M., Shay, J. W., & Wright, W. E. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-03-0207 · Cited by 293
Self-citationIn vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor
Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E., & Shay, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1215 · Cited by 271 · cited 6×
“Xenograft models showed that GRN163L works to inhibit tumor growth, prevent growth of metastases, and sensitizes tumors to conventional chemotherapy agents [61,68].”
InfluentialSelf-citationTelomerase-Specific Replication-Selective Virotherapy for Human Cancer
Kawashima, T., Kagawa, S., Kobayashi, N., Shirakiya, Y., Umeoka, T., Teraishi, F., Taki, M., Kyo, S., Tanaka, N., & Fujiwara, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1075-3 · Cited by 262
Djojosubroto, M. W., Chin, A. C., Go, N., Schaetzlein, S., Manns, M. P., Gryaznov, S., Harley, C. B., & Rudolph, L. K. (2005) · Hepatology · doi:10.1002/hep.20822 · Cited by 151 · cited 4×
“Xenograft models showed that GRN163L works to inhibit tumor growth, prevent growth of metastases, and sensitizes tumors to conventional chemotherapy agents [61,68].”
InfluentialHochreiter, A. E., Xiao, H., Goldblatt, E. M., Gryaznov, S. M., Miller, K. D., Badve, S., Sledge, G. W., & Herbert, B.-S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2760 · Cited by 146 · cited 2×
“Chronic exposure to GRN163L has been shown to inhibit telomerase and cause telomere shortening in cancer cell lines derived from diverse origins, including tumors of the brain, breast, bladder, liver, lung, prostate and stomach [56,61,66,68,75–78].”
Antiadhesive Effects of GRN163L—An Oligonucleotide N3′→P5′ Thio-Phosphoramidate Targeting Telomerase
Jackson, S. R., Zhu, C.-H., Paulson, V., Watkins, L., Dikmen, Z. G., Gryaznov, S. M., Wright, W. E., & Shay, J. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2306 · Cited by 72 · cited 1×
“The template region of the telomerase RNA (hTR) offers an accessible substrate for direct enzymatic inhibition using oligonucleotide-based small molecule inhibitors [56–71].”
Self-citationAntitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts
Ozawa, T., Gryaznov, S. M., Hu, L. J., Pongracz, K., Santos, R. A., Bollen, A. W., Lamborn, K. R., & Deen, D. F. (2004) · Neuro-Oncology · doi:10.1215/s1152851704000055 · Cited by 56
Cited by
Armanios, M., & Blackburn, E. H. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3246 · Cited by 982
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Jafri, M. A., Ansari, S. A., Alqahtani, M. H., & Shay, J. W. (2016) · Genome Medicine · doi:10.1186/s13073-016-0324-x · Cited by 716
“The main objective of anti-telomerase therapeutics is to selectively induce apoptosis and cell death in cancer cells while minimizing the effects on normal cells [57].”
BackgroundSelf-citationRole of Telomeres and Telomerase in Aging and Cancer
Shay, J. W. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0062 · Cited by 668
Self-citationRole of telomeres and telomerase in cancer
Shay, J. W., & Wright, W. E. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.10.001 · Cited by 523
Self-citationDNA helicases involved in DNA repair and their roles in cancer
Brosh, R. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3560 · Cited by 344
Metadata
- Authors
- Buseman, C. M., Wright, W. E., & Shay, J. W.
- Venue
- Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 730
- Issue
- 1-2
- Pages
- 90-97
- ISSN
- 0027-5107 (ISSN-L)
- 1386-1964
- OpenAlex
- W2060896826
- Cited by
- 148
- References
- 32
- FWCI
- 9.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.